Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free

Did Elicio Therapeutics Beat Earnings?

Elicio Therapeutics (ELTX) reported Q2 '26 revenue of $0.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Elicio Therapeutics’s job postings, web traffic, and employee business outlook. See the full ELTX stock analysis or the earnings calendar for upcoming reports.

Elicio Therapeutics Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue—1.2M——————
Gross margin—-26.2%——————
Operating margin—-1,155.7%——————
Net income-19M-14M-11M-11M-10M-7.7M-12M-8.2M
Net margin—-1,201.0%——————
EPS————————

Elicio Therapeutics Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Elicio Therapeutics’s quarterly revenue moved from $0 to $0.

When Is Elicio Therapeutics’s Next Earnings Date?

Elicio Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the ELTX earnings calendar.

Frequently Asked Questions: Elicio Therapeutics Earnings

Elicio Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Elicio Therapeutics reported Q2 '26 revenue of $0.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the ELTX AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.